Form 4: Bristol-Myers Squibb Director Gerald L. Storch Reports Acquisition of Deferred Share Units

Director Gerald L. Storch reports acquiring deferred share units of Bristol-Myers Squibb, convertible to common stock upon departure from the board or at a specified future date.

Summary

• On March 31, 2024, Gerald L. Storch, a director of Bristol-Myers Squibb, acquired 691.499 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Storch ceases to be a director or at a previously specified future date.
• The price of the deferred share units was $54.23.
• Following the transaction, Storch beneficially owns 88,158.649 shares, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction by a company director.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company director, which is a common occurrence in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the holdings of a company director.

Key Dates